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INTRODUCTION 
Old medical literature states that, the term dyscrasia (in Greek language meaning 
“bad temperament”), was used to indicate disease. Now, the phrase blood dyscrasia refers 
to disorders of the cellular elements of the blood, indicating a pathologic condition.(1)  A 
change in the total number of red blood cells in a patient is referred to as either 
polycythemia (Increased RBCs) or anemia (decreased RBCs). An increase in population 
of atypical or neoplastic white blood cells within the blood indicates leukemia.(2) 
Bleeding disorders or coagulopathies can be caused by a decrease in number of platelets 
in the blood termed as thrombocytopenia, or abnormal platelet function. These blood 
disorders often overlap.(1)  The columns of both arterial and venous blood in the fundus of 
eye lie exposed, so that they can be observed through the ophthalmoscope with 
appropriate magnification, or photographed. The ophthalmogist is often the first witness. 
Its diseases may present in diverse sites before the patient reaches the haematologist, 
whose analysis gives the final diagnosis. (3) 
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NEED FOR THE STUDY 
OCULAR MANIFESTATIONS IN BLOOD DYSCRASIAS 
The ocular manifestations of blood dyscrasias are frequently observed as indicated 
by clinical and pathologic studies. The ocular fundus gives an unparalleled direct view of 
the hematologic effects of blood dyscrasias, apart from the hemorrhagic and infiltrative 
complications observed in the skin and mucous membranes. The ophthalmologist, by 
observing the characteristic changes in the retina, may be the first member of the medical 
team to identify the hematologic effects of a blood dyscrasia.(3) 
The typical ophthalmoscopic findings are not pathognomonic of blood dyscrasias 
and may be observed in many conditions involving the eye (i.e., diabetes, hypertension, 
collagen vascular disease). However, the distribution and pattern of the retinal findings in 
blood dyscrasias are characteristic. If these characteristic findings are identified on 
ophthalmoscopy, then further investigations may reveal a blood dyscrasia allowing for 
early referral for treatment by the physician.(4) 
Our study aims to observe the incidence of the ocular manifestations of blood 
dyscrasias, their diagnostic and prognostic importance to the disease and the resolution or 
progression with treatment. 
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HISTORICAL REVIEW 
In the 1860s, Liebreich first described leukemic retinopathy. Since that time, 
virtually all intraocular structures have been found to become involved. 33 different 
ocular anomalies were listed by Goldbach from among the 242 leukemias at John 
Hopkins Hospital; of this majority were seen in the fundus.(2) 
Patients have been reported with leukemic infiltrates of the optic nerve, choroid, 
retina, iris, ciliary body, and anterior chamber. In multiple myeloma, Bronstein reported 
plasma cells floating free in the anterior chamber and adhering to the posterior cornea. A 
patient with polycythemia described by Lousea et al. had a one-and-a-half syndrome 
from an infarction of the pons.(5) 
In the study performed by Jabaily et al., visual disturbances occurred in 6 of 33 
patients and included scintillating scotomas, episodic dimming of vision, and amaurosis 
fugax . Murphy et al. reported that 10 of 37 patients with essential thrombocythemia had 
visual phenomena as part of their disease. Among 33 patients reported by Michiels et al., 
10 had visual symptoms: transient monocular blindness in 3, and blurred vision in 10 
patients.(6) 
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ANEMIAS 
Definition:      
Anemia is defined as a  low Hb level (< 13 g Hb/dL in men and < 12 g Hb/dL in 
women),  decreased number of circulating RBC (< 4.4 millions/cumm in men and < 3.8 
millions/cumm in women), or both, resulting in  diminished oxygen-carrying capacity of 
the blood. 
General manifestations are due to: 
i)     Decreased Hb concentration (pallor of skin, conjunctiva and nail beds), 
ii)    Tissue  hypoxia due to deficient oxygen transport (weakness, easy 
fatigability, exertional dyspnea), and 
iii)      Recruitment of compensatory mechanisms (cardio-circulatory, biochemical 
and medullar) aimed at increasing cardiac output and oxygen delivery to the 
tissues. 
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Classification: 
1) Morphologic classification (according Hb, Ht red cell indices and the peripheral 
blood smear)subdivides anemias into: 
1. Microcytic hypochromic anemias 
2. Macrocytic normochromic anemias 
3. Normocytic normochromic anemias 
2) Functional classification (according the reticulocyte count) comprises: 
1. Regenerative anemias (> 3%) 
2. Aregenerative anemais (< 3%) 
3) Etiopathogenic classification: Anemias may result from: 
4) Decreased red cell production (decreased erythropoiesis) 
5) Increased red cell destruction (increased hemolysis) 
6) Anemias due to decreased erythropoiesis 
7) Decreased erythropoisis  
8) Nutrional deficiency: 
1. Deficiencies in hemoglobin synthesis: 
a. Iron deficiency anemia 
b. Sideroblastic anemia 
2. Deficiencies in DNA synthesis: 
a. Vit. B12 deficiency 
b. Folate deficiency 
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9) Bone marrow failure: 
a) Pluripotential stem cell failure: 
i)   Aplastic anemia 
ii)   Anemia of leukemia and of myelodysplastic syndromes 
b) Erythroid progenitor cell failure: 
i)  Anemia from chronic disease/inflammation 
ii)  Anemia from chronic kidney disease 
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1. IRON DEFICIENCY ANEMIA 
Definition:  
The most common form of anemia worldwide characterized by microcytosis, 
hypochromia ,decreased iron stores(low ferritin) and low serum iron. 
Iron metabolism:  
 Iron balance depends on adequate intake, absorption, recycling and loss. The total 
body iron content is about 3.5 g in men and 2.5 g in women and is divided into functional 
and storage compartments. Functional iron (80%) is found in hemoglobin, myoglobin and 
iron-containing enzymes whereas the  storage compartment is represented by ferritin 
(rapid available iron, a combination of iron and apoferritin), and hemosiderin. 
Hepatocytes are the main site of ferritin storage and minute quantities are present in 
plasma in equilibrium with the intracellular ferritin. 
Hemosiderin is mainly stored in the macrophage-monocyte system as aggregates 
or crystals of ferritin with the apoferritin partially removed. 
2. VITAMIN B12 AND FOLIC ACID DEFICIENCY ANEMIAS 
Definition:  
Megaloblastic, macrocytic, normochromic anemias that share as common feature 
an impairment of DNA synthesis. 
General features:  
Both B12 and folate are cofactors in the synthesis of thymidine, one of the four 
bases in DNA. The inadequate DNA synthesis results in defective nuclear maturation and 
a delay in cell division (cell size increases) whereas cytoplasmic maturation and 
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hemoglobin accumulation proceed normally,leading to nuclear-to-cytoplasmic 
asynchrony. 
Bone marrow:  
Megaloblastic changes are detected at all stages of erythropoiesis 
(promegaloblasts, megaloblasts) with a decreased production of mature RBC and release 
into the peripheral blood, causing anemia. The megaloblasts may undergo autohemolysis 
in the marrow or are destroyed by phagocytic cells in the marrow (ineffective 
erythropoiesis). Megakaryocytes are abnormally large too. 
Peripheral blood:  
The presence of abnormally large red cells (high MCV) -macrocytes and macro-
ovalocytes is highly characteristic. Large and hypersegmented neutrophils may be seen 
secondary to the delay in mitotic division. The impairment of DNA synthesis is systemic, 
and affects other rapidly dividing cells in the body, e.g. gastrointestinal epithelial cells. 
Since the megaloblastic features are indistinguishable morphologically in folate and B12 
deficiencies, diagnosis is established by laboratory tests (serum B12 and folate levels). 
3. APLASTIC ANEMIA 
Definition:  
A normochromic normocytic anemia due to a defect of the pluripotent stem cells 
responsible for primary hematopoietic failure with: 
• Marked Bone Marrow Hypocellularity & fatty replacement of bone marrow – 
Pancytopenia (anemia,neutropenia,thrombocytopenia) in the peripheral blood 
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Etiology: 
a) In 2/3 of the cases-idiopathic Aplastic anemia (no detectable initiating factor). 
b) The rest of the cases occur secondary to: 
i) Chemical toxins (benzene, chlorinated hydrocarbons) 
ii) Drugs: Alkylating agents and Antimetabolites used in cancer therapy (dose 
related effect) and chloramphenicol, phenylbutazone (idiosyncratic 
mechanism) 
iii)    Viral infections(Hepatitis, AIDS, Mononucleosis) 
iv)   Autoimmune disorders  (SLE, Hashimoto Thyroiditis) 
Pathogenesis: 
Two major pathogenetic theories exist: 
1. An extrinsic immune-mediated suppression of marrow precursors triggered by 
exposure to chemicals, infectious agents, etc. with the production of cytokines (TNF and 
IFN) that are directly responsible for the suppression of haematopoiesis. 
2. An intrinsic abnormality of stem cells (reduced proliferative capacity) Clinical 
problems result from anemia (weakness, fatigue), leukopenia (infections) and decreased 
platelets (bleeding). Bone marrow transplantation has been successful, especially in 
patients less than 40 years old. 
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4.ANEMIA FROM CHRONIC DISEASE/INFLAMMATION 
Definition:  
characterized by: 
• low serum iron level 
• increased ferritin level(reflecting the excessive iron stores ). 
Etiology: 
1)      Chronic infections (AIDS, osteomyelitis) 
2)      Chronic inflammations (Inflammatory bowel disease) 
3)     Autoimmune disorders (Lupus Erythematosus, Rheumatoid   Arthritis) 
4)      Cancer (Hodgkin’s disease) 
Pathogenesis: 
Microorganisms, injured tissues, autoimmune dysregulation and tumor cells lead to   
T–cell activation and production of cytokines  ( IL-1, IL-6, TNF-Į, IFN) that are 
responsible for: increased production of hepcidin by the liver(IL-6) which inhibits iron 
release from hepatocytes, enterocytes and macrophages . 
• macrophage sequestration of iron with decreased serum iron level & availability 
for Erythropoiesis 
• macrophage activation with increased splenic destruction of red cells 
(hypersplenism- RBC lifespan is decreased by 20 to 30%) 
• reduced production of erythropoietin(EPO) and/or resistance to EPO 
• resulting in decreased Erythropoiesis 
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5. HEMOLYTIC ANEMIAS 
Hemolytic anemias are characterized by shortened red cell survival. Increased 
Erythropoietin production results in increased red cell production with a Reticulocytosis 
to compensate for the anemia.Red cell destruction can occur within the spleen 
macrophages (Extravascular hemolysis) or within circulation (intravascular hemolysis). 
Another feature is the retention of Hb degradation products in the body increased serum 
levels of indirect bilirubin > 2.5 mg/dl causing jaundice. 
Extravascular hemolysis: Destruction of red cells in the mononuclear phagocytic 
system(spleen, liver) – the normal place of physiologic hemolysis of senescent 
erythrocytes. 
Damaged or abnormal RBC are removed in spleen, where Hemoglobin is broken 
down Intracellularly.  Free Hemoglobin is not released directly into the blood and urine, 
but hemoglobin breakdown products are increased (hyperbilirubinemia) and jaundice 
may result. 
Spleen and liver may become enlarged since these are sites of removal of RBC 
from the circulation. Chronically elevated levels of bilirubin can promote formation of 
gallstones. Intravascular hemolysis leading to destruction of RBC within the circulation. 
6. THALASSEMIA 
Definition:  
Is an inherited defect (Autosomal dominant) that results in diminished  or absent 
synthesis of either the alpha or beta globin chains of hemoglobin.  The type of 
Thalassemia is named for the globin chain produced in reduced amounts. Decreased 
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globin production leads to decreased hemoglobin production and anemia, as major 
manifestation. In addition, precipitation of the relative excess of the other globin chain 
within RBC is responsible for membrane damage and premature destruction of RBC 
precursors in the marrow (ineffective erythropoiesis) and spleen (extravascular 
hemolysis). 
Clinical manifestations vary from severe transfusion-dependent anemia and iron 
overload to mild anemia. In almost all cases there is a moderate to marked microcytosis 
with target cells and basophilic stippling of the red cells present on the blood smear. 
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POLYCYTHEMIA: 
The opposite of anemia is polycythemia, which is characterized by:  An increase 
in the number of circulating red cells-an increase of the haematocrit (Ht) (over 45% in 
females, over 48% in males). 
The pathophysiological consequences of the increasing haematocrit are: 
• an increase of blood viscosity, which can lead to an increased risk of thrombosis 
and a decrease in the tissues’ blood and oxygen supply, thus leading to hypoxia 
and an overload of the heart function. 
The increased medullary activity will be accompanied by an increased cellular 
destruction, which can lead to a high level of uric acid (risk for developing gout). 
Polycythemia is divided into: 
• Relative polycythemia (erythrocytosis) (the red cell mass is normal, but the plasma 
volume is reduced) 
• Absolute polycythemia (erythrocytosis) (a true increase in red-cell mass). 
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WHITE BLOOD CELLS 
1) NON – MALIGNANT disorders of white blood cells 
a) Disorders due to a abnormal number of white blood cells 
1. Leucocytosis 
2. Leucopenia 
b) Disorders due to abnormal function of white blood cells 
2) MALIGNANT disorders of white blood cells 
a) WHO classification of white cells neoplasm 
b) Leukemia 
c) Lymphomas 
d) Plasma cell neoplasm 
NON – MALIGNANT DISORDERS OF WHITE BLOOD CELLS 
A. Disorders due to abnormal number of white blood cells: 
1. Leucocytosis: increase of the number of white cells > 10,000/cumm 
2. Leucopenia: decrease of the number of white cells < 4,000/mm 
MALIGNANT DISORDERS OF WHITE BLOOD CELLS 
Hematological malignancies have been classically divided by whether the 
malignancy is mainly located in the blood (leukemia) or in the lymph nodes 
(lymphomas). 
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LEUKEMIA:  
are   primary  neoplasm of the bone marrow (BM) With  characteristic spilling 
over of the malignant cells into peripheral circulation. 
LYMPHOMAS:  
are   primary  neoplasm of lymph nodes/lymphoid tissues that   usually  do not 
involve peripheral spill over of malignant cells. 
LEUKEMIAS 
Definition:  
malignant disorders resulting from an abnormal proliferation in the bone marrow, 
with invasion of the blood stream. 
Classification: 
I. According to the evolution: 
1. Acute leukaemia:   
in which accumulation of immature cells (blasts) suppresses normal 
hematopoiesis. 
2. Chronic leukaemia:  
characterized by an abnormal proliferation of the mature cells having better 
prognosis and longer evolution. 
II. According to the abnormal cell type: 
1. Myeloid Leukemia  (Acute, Chronic) 
2. Lymphoid (lymphocytic)  Leukemia  (Acute, Chronic) 
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Consequences: 
 in blood cell number and function 
a) Infections : Most common cause of death 
Due to severe infections (neutropenia, impairment of phagocytic function and 
lymphocyte function) 
b) Haemorrhage :Due to thrombocytopenia or liver disease 
c) Anemia : Due to replacement of RBC precursors by cancer cells 
Prognosis of leukemia: 
1.Severity of anemia reflects severity of disease 
2. Invasion of vital organs (enlargement of spleen, liver, brain, lung, and lymph nodes) 
ACUTE LEUKEMIA 
Definition: acute leukemia  develop as a consequence of an abnormal proliferation 
of blasts (immature cells) that leads to hematopoietic suppression. 
Classification: 
1. Acute Myeloid leukemia (AML) 
2. Acute Lymphoid leukemia(ALL) 
CHRONIC LEUKEMIA 
Definition: chronic leukemia develop as a consequence of increased proliferation 
and accumulation of differentiated, mature leukemia cells. 
Classification: 
1. Chronic myeloid leukemia (CML) 
2. Chronic lymphoid leukemia (CLL) 
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LYMPHOMAS 
Definition:  
malignant disorders caused by abnormal proliferation of the cells that reside in the 
lymphoid tissues. Morphologically, these neoplasms are solid tumors of the lymphoid 
tissue that do not lead to peripheral blood invasion. However, if such an invasion were to 
take place, it will be described as a leukemia phase of the lymphoma. 
Classification: 
• Hodgkin’s lymphoma 
• Non – Hodgkin’s lymphoma 
Both diseases invade the lymphoid tissues, but the difference between them resides in 
the biological, clinical and prognosis features. 
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OCULAR FEATURES IN DISORDERS OF RBC: 
RBC disorders that ophthalmologists frequently encounter include anemias and 
sickle cell disease. 
• Anemia:  
Anemia is a common condition occurring when the level of healthy 
RBCs/erythrocytes or hemoglobin, is subnormal. Causes include increased blood loss, 
inadequate production of RBCs by the bone marrow (aplastic anemia) and destruction of 
RBCs (hemolytic anemia). Additional causes include iron, vitamin B12 (pernicious 
anemia) or folic acid deficiencies, which are related to poor nutrition or absorption 
defects in the gastrointestinal tract. General symptoms include pallor of the skin or nail 
beds, weakness, headaches, shortness of breath, gastrointestinal disturbances, fever, and 
numbness or coldness of extremities. 
Diagnostic tests: 
CBC-The key components of the complete blood count (CBC) indicating anemia 
are decreased RBC count, low hemoglobin (Hgb) and reduced hematocrit (HCT). MCV-
Mean corpuscular volume, a measurement of average size of the red blood cells, helps to 
identify the type of anemia. The normal range of MCV is from 80fL to 100fL. The 
anemia is classified as microcytic if MCV falls below 80fL; if above 100fL, the anemia is 
classified as macrocytic. A major cause of microcytic anemia is iron deficiency and 
macrocytic anemia is folic acid or vitamin B12 deficiency. 
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Iron is a major component of hemoglobin, essential for its proper function in transporting 
oxygen. Additional testing such as serum ferritin (a major storage form of iron) test or 
total iron binding capacity (TIBC) test (which is a measure of transferrin, a protein that 
helps transport iron in the blood) are needed to make a diagnosis of iron deficiency 
anemia. 
Other  investigations- Folic acid or vitamin B12 serum levels or a bone marrow 
biopsy to rule out a plastic anaemia. 
Many systemic diseases such as cancer, inflammatory diseases and pregnancy may 
present with anaemia. So appropriate investigations may be necessary to identify the 
underlying cause of the anemia. 
OCULAR FEATURES IN ANEMIA: 
Ocular changes in anemia include conjunctival pallor and hemorrhages. Anemic 
retinopathy and other retinal changes are well established  complications of anemia. 
Common retinal findings include intraretinal hemorrhages, Roth’s spot hemorrhages, 
cotton-wool spots, retinal exudates, venous dilation and optic nerve pallor. The exact 
pathophysiology of the retinopathy is not clearly understood, but seems to be related to 
retinal hypoxia. These changes are generally seen in severe anemia or when 
thrombocytopenia is present. 
The normal color of the ocular fundus is derived from retinal pigment epithelium 
(RPE), choroidal melanocytes, and  blood in the retinal and choroidal vasculature. The 
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retina is normally transparent. In patients with severe anemia, the fundus may appear pale 
and the retinal vessels may be less red than normal. 
Anaemia is the commonest haematological disorder presenting with variety of 
ocular manifestations. It can affect every part of the eye and adnexa but predominant 
features are conjunctival pallor and retinal haemorrhages. Other retinal manifestations 
include venous and arteriolar tortuosity, cotton wool spots, macular star and papilledema. 
Their increased incidence is correlated with severity of anaemia. The substrate for retinal 
metabolism is reduced in anaemia and makes it prone for hypoxic damage. 
Anemic retinopathy has been associated with diseases of the red blood cell 
elements or as a secondary manifestation of other systemic diseases, and it should be 
noted that many of the systemic diseases involved may be associated with similar retinal 
findings and are not exclusive of anemia per se. Hence, it has been appropriately 
suggested that since anemic retinopathy is almost always reversible with correction of the 
anemia, one should be reluctant to ascribe retinal changes entirely to concomitant 
systemic disease until restoration of normal haemoglobin levels and fundoscopic re 
evaluation. 
In optic disc edema, nerve fiber swelling in the optic disc and peripapillary retina 
is present and often associated with flame-shaped hemorrhages, whitish punctate lesions 
(secondary to obstructed axoplasmic flow), and peripapillary CWSs. On ophthalmoscopy, 
the optic disc and peripapillary retina appear elevated and the margins of the optic disc 
are blurred. Optic disc edema is usually bilateral and may be due to elevated intracranial 
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pressure (i.e., papilledema)  secondary to hemorrhage or a mass effect associated with  
blood dyscrasias (i.e., meningeal infiltration, granulocytic sarcoma). The disc edema may 
also be secondary to serum (blood) hyper viscosity and may resemble that seen in CRVO. 
Less commonly, direct infiltration of the optic nerve or optic disc may cause marked 
optic disc edema. 
RETINAL HEMORRHAGES: 
The configurations of retinal hemorrhages depend on where they are located 
within the retina. In blood dyscrasias, flame-shaped and dot-blot hemorrhages are the 
most commonly and frequently encountered. Nerve fibre layer houses the flame-shaped 
hemorrhages whereas the inner nuclear and outer plexiform layers house the dot-blot 
hemorrhages. Seen beneath the internal limiting membrane of the retina are large boat or 
blot-shaped hemorrhages i.e., sub-ILM hemorrhage which are large superficial retinal 
hemorrhages, which extend into the vitreous cavity after breaking through the internal 
limiting membrane. Retina of patients with blood dyscrasia contain white-centred 
hemorrhages and red-centred infiltrates. Leukemic embolus or more commonly platelet-
fibrin thrombus may be the reason behind the white centre. Red centred infiltrates are of 
blood which may be seen in association with leukemic retinal infiltrate or cotton wool 
spot. 
MICRO-ANEURYSMS: 
Micro-aneurysms are defects which are seen as outpouchings of the retinal 
capillary wall.  On ophthalmoscopic  examination, they appear as small reddish spots in 
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the retina. In diabetic retinopathy, they are visualized in the posterior aspect of the 
fundus. Microaneurysms are also seen in certain other conditions like leukemia and 
plasma cell dsycrasia. In blood dyscrasias these lesions are visualized in the periphery of 
the retina whereas in diabetic retinopathy they are seen in the posterior retina. 
 Duke and co-workers in his study which involves trypsin digestion of flat mounts 
of the retina, found that  relative preservation of pericytes in patients with chronic 
leukemia as compared with the marked loss of pericytes in diabetic retinopathy. The 
lesion’s globular shape, its location on the capillary’s venous side predominantly and 
intraluminal and intramural periodic acid Schiff positive deposits are the common 
pathological features between micro aneurysms of Blood dyscrasias and diabetes.  
Factors like increased venous pressure (CRVO), increased blood viscosity with 
secondary increase in venous pressure (hyperviscosity syndrome associated with plasma 
cell dyscrasias) and anoxia (anemia) play a vital role in the formation of micro-
aneurysms in cases of blood dyscrasias. 
RETINAL EDEMA: 
Hyper permeable or leaky retinal capillaries is also a causative factor of focal or 
generalized retinal edema, in addition to hard exudates formation. Normally the retina is 
transparent, however there is greying or mild pacification of the retina on 
ophthalmoscopic examinationin retinal edema. In long-standing cases of retinal edema, 
cystic degeneration of the retina may occur. Cystoid macular edema is when the retinal 
edema which is localized to the macular region. From a histological point of view, cysts 
in CME consist of eosinophilic proteinaceous material which is located in the outer 
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plexiform layer and in the inner nuclear layer of retina, to a lesser extent. Observations of 
lipid-laden macrophagesin the region of cystoid macular edema have been made 
occasionally. In hyperviscosity syndromes induced by blood dyscrasias, retinal edema 
may be seen, as with hard exudates. Blood dyscrasias induced CME show response to 
specific therapy for CME (i.e. Acetazolamide ) and with treatment of the underlying 
disease like bone marrow transplantation in CME, CME resolves completely. 
COTTON WOOL SPOTS: 
Otherwise called soft exudates, are micro-infarctions present in the retina’s nerve 
fibre layer. When focal retinal ischemia occurs due to pre-capillary arteriolar occlusion, 
normal axoplasmic flow is blocked. They are whitish superficial lesions on the retina 
with feathery borders in association with small retinal hemorrhages. These lesions resolve 
and fade, developing an area of depression in the retina which is secondary to inner 
retinal ischemic atrophy. Microscopically, they are fusiform thickenings of the nerve 
fibre layer with globular cystoids bodies [swollen ganglion cell axons with cellular 
organelles like mitochondria, endoplasmic reticulum and neurofilaments which are 
degenerated]. In patients afflicted with blood dyscrasias induced retinopathy, CWSs are 
seen. In one report, in the absence of diabetes and hypertension, if a single CWS is seen 
in each eye, diagnosis of MM is made. In a prospective study of 54 newly diagnosed 
patients with acute leukemia, Abu El-Asrar and co-workers(19) reported that patients with 
CWSs had significantly lower mean and median survival times than those patients 
without CWSs. Poor prognostic sign for a patient’s survival in acute leukemia is the 
presence of CWSs. 
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Severe anemia is a prominent risk factor in the development of CWSs in patients 
afflicted with blood dyscrasias. Holt and Gordon-Smith(3) observed CWSs in 14 patients 
with severe anemia with a mean hemoglobin concentration of 5.6 g/100 ml.In contrast, 
Guyer and co-workers(4)found no statistically significant association between the 
presence of CWSs and hematologic parameters (including the hematocrit) in their 
prospective series. CWSs occur due to pre-capillary arteriolar occlusion by leukemic cells 
or by platelet-fibrin thrombi. 
VASCULAR OCCLUSIONS: 
Visual disturbances in patients with essential thrombocythemia are related to 
thrombotic, hemorrhagic, and possibly vasomotor phenomena.The ocular abnormalities 
seen in patients with polycythemiavera are similar to those seen in patients with other 
hyper viscosity syndromes. Their severity is related to that of the polycythemia and its 
duration. Many patients develop engorgement of the conjunctival and retinal vessels. The 
associated ischemic disorders of the eye may become manifest as dilated, tortuous 
vessels, retinal hemorrhages, central retinal artery occlusion (CRAO), central retinal vein 
occlusion (CRVO), and anterior ischemic optic neuropathy (AION). CRVO may be 
bilateral.  
As mentioned above, papilledema may result from the effects of thrombosis of the 
cerebral venous sinuses. Optic disc swelling may also result from local vascular changes 
related to hyper viscosity. 
It is important to rule out other ocular and concomitant systemic diseases, as the 
ocular changes of anaemia are non-specific and may closely resemble other conditions. 
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The ocular complications are usually reversible with correction of the anemia. Pallor of 
the optic nerve requires imaging studies. These patients should be monitored frequently 
with three to six month follow-up evaluations. 
SICKLE CELL DISEASE:  
It is an inherited autosomal recessive disorder due to abnormal hemoglobin 
resulting in a crescent-like, or sickle-shaped RBCs usually in association with decreased 
oxygen. Normal blood flows is prevented by the sickled RBCs, leading to increased 
blood viscosity and decrease the RBCs’ ability to carry oxygen, which results in chronic 
haemolysis and vaso-occlusive events that produces tissue and organ damage. 
The four most common hemoglobin variants include: sickle cell anemia (SS), 
associated more with systemic complications; sickle cell thalassemia (S-thal) and sickle 
cell C disease (SC), more commonly associated with severe ocular complications; and 
sickle cell trait (AS), occuring when one normal hemoglobin gene and one sickle 
hemoglobin gene are inherited. 
The diagnosis begins with observation of ocular changes, which result from the 
sickling of RBCs within small vessels leading to micro vascular occlusion. The resulting 
features include ischemia, hypoxia, infarction, “sea-fan” neovascularisation and 
fibrovascularization. 
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POLYCYTHEMIA: 
Polycythemia is a sustained increase in erythrocyte count, blood haemoglobin 
Concentration, and hematocrit. Polycythemia may be secondary to a myriad of conditions 
causing chronic hypoxemia or elevated erythropoietin production. Polycythemia vera is a 
myeloproliferative disorder of middle or later life often associated with leukocytosis and 
thrombocytosis. 
Late in the course of polycythemia vera, there is a transition to a disease state that 
involves myeloid metaplasia with myelofibrosis. This is associated with extramed ullary 
hematopoiesis (blood cell production outside the bone marrow). This process rarely 
occurs outside the cranium. However, there have been two cases of extramedullary 
hemato-poiesis invading the optic nerve sheath. On computed tomography scanning, this 
appears as a well-demarcated retro bulbar mass along the optic nerve. 
Haematological diseases, such as anaemia encompass a wide spectrum of 
disorders ranging from benign to malignant conditions that can present with ocular 
involvement. Mostly the ocular manifestations may be the initial indication of an 
underlying haematological disorder, which often requires a laboratory work-up to clinch 
a final diagnosis. 
THROMBOCYTOPENIA: 
Idiopathic thrombocytopenia is a disease primarily caused due to increased platelet 
destruction with formation of specific antibodies against platelet membrane glycoprotein. 
ITP often follows an in infection in the acute form and shows spontaneous resolution 
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while in chronic ITP, it persists for more than 6 months. Thrombocytopenias are 
commonly related to intake of specific drugs such as Quinolones, Sulphonamides. 
LEUKEMIA 
Leukemia are neoplasm of the hematopoietic system. Leukemic cells show a poor 
responsiveness to normal regulatory mechanisms, have a diminished capacity for normal 
cell differentiation, and can have malignant transformation occurring at any stage of 
haematopoiesis. Abnormalities may affect the lymphopoietic or myelopoietic arms of 
hematopoiesis, resulting in a myelogenous or lymphocytic leukemia, respectively. 
Leukemia can occur in a rapid and aggressive form (acute) or an indolent form (chronic). 
These combinations account for the four broad categories of leukemia: 
(1) Acute Myelogenous Leukemia (AML), 
(2) Acute Lymphocytic Leukemia (ALL), 
(3) Chronic Lymphocytic Leukemia (CLL), And 
(4) Chronic Myelogenous Leukemia (CML). 
Although all types of leukemias can affect patients at almost any age, typically 
AML affects males older than 50 years, ALL tends to affect children younger than 15 
years of age, CLL affects patients older than 50 years of age, and CML affects patients in 
the 5th decade with a slight male predominance [6] 
Almost every structure in the orbit, the globe as well as adnexa may be involved in 
these conditions. Lymphomas of the eye are mostly of the B cell lineage. 
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PLASMA CELL DYSCRASIAS/ PARAPROTEINEMIAS: 
Plasma cell dyscrasias are characterized by malignant proliferation of B cells with 
subsequent overproduction of immunoglobulin (antibodies). 
They are classified into three major types: 
(1) Multiple myeloma with overproduction of either IgG, IgA,IgD or IgE; 
(2) macroglobulinemia with overproduction of IgM; and 
(3) light- and heavy-chain diseases. 
OCULAR CHANGES IN MALIGNANT DISEASES OF BLOOD 
The ocular changes in leukemia are predominantly divided into anterior segment 
manifestations and posterior segment manifestations.Anemia, Thrombocytopenia, 
elevated white blood cell count and blood or serum hyperviscosity are the contributing 
factors which promote the development of retinal hemorrhages in patients with blood 
dyscrasias.(9) Rubenstein and co-workers in a study conducted in a group of 67 patients 
found that retinal hemorrhages presented more commonly in patients with both anemia 
and thrombocytopenia than when either is present alone. It was postulated by the same 
authors that in an anemic patient, ocular bleeding could be attributed to 
thrombocytopenia. 
Holt and Gordon-Smith in their study conducted on 152 patients with blood 
diseases, (10) found that retinal hemorrhages were seen more commonly in leukemic 
patients with very severe anemia and thrombocytopenia with higher percentage of 
circulating blast cells. The findings of the prospective study conducted by Guyer and 
colleagues in a group of 117 patients with acute leukemia further supported that 
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thrombocytopenia plays a significant role in the pathogenesis of retinal hemorrhages. 
(11)However Jackson and co-workers in their study on 63 newly diagnosed acute leukemia 
patients, saw no allegiance between intraretinal hemorrhages and hemoglobin level or 
platelet count. But they also found out that higher median white blood cell count was 
seen in patients with intraretinal hemorrhages than in patients without intraretinal 
hemorrhages providing the conclusion that in the pathogenesis of retinopathy in acute 
leukemia, high white blood cell count is as important as anemia and 
thrombocytopenia.(12) 
Perivascular sheathing and retinal vasculitis   ( leakage from retinal vessels on 
fluorescein angiography) have been prominent ocular findings in patients with certain 
blood dyscrasias, including human T-lymphotropic virus 1 (HTLV-1)-associated adult T-
cell leukemia/lymphoma, cryoglobulinemia, hairy cell leukemia, and, rarely, MM.Kim 
and coworkers described a patient with relapsing acute lymphoblastic leukemia who 
presented with a retinal vasculopathy resembling frosted branch angiitis and an 
infiltrative optic neuropathy that resolved with local radiation and intrathecal 
chemotherapy.(13) 
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ANTERIOR SEGMENT MANIFESTATIONS: 
Sclera: 
Infiltration of the sclera or episclera by leukemic cells is usually found at autopsy 
and rarely produces any clinical symptoms or signs. The cells are most often present in 
the episclera, with a perivascular distribution. (12) 
Conjunctiva: 
Involvement of the conjunctiva most often occurs in patients with lymphocytic 
leukemia, but it also occurs in other types. Cellular invasion ccurs at all levels of the 
substantia propria. It may be diffuse or patchy, although it tends to concentrate around 
blood vessels. In some cases the involvement consists of visible nodules with 
surrounding injection resembling areas of focal episcleritis, whereas in others there is 
only slight swelling of the conjunctiva, and in still others there is diffuse and substantial 
swelling leading to limitation of eye movements.(13) As with other ocular manifestations 
of leukemia, conjunctival involvement may occur at any time during the course of the 
disease and may even be its first sign. The most frequent ocular findings were seen in 
conjunctiva (33.4%) among leukemics in a study in Poland (8). Multiple myeloma is one 
of the causes of a salmon patch conjunctival lesion. 
Cornea: 
As cornea is avascular, the invasion of cornea by leukemic cells is not expected. 
But leukemia  may cause formation of a sterile ring like ulcer associated with iritis and 
formation of pannus. This ring lesion also called an immune ring, may be observed even 
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prior to the diagnosis of leukemia and hence a patient presenting with a corneal ring ulcer 
should be evaluated thoroughly for systemic illnesses, including leukemias. (14) 
Multiple myeloma frequently presents with a complication of corneal precipitates 
that have been reported for over 70 years. These crystalline corneal precipitates have 
been reported to be deposits of immunoglobulins, primarily IgG. The source of these 
immunoglobulins have been attributed to high immunoglobulin levels in tears or aqueous 
humor leading to corneal crystals, the immunoglobulins which reach the cornea through 
limbal vessels as well as from the keratocytes supplying the precipitated 
immunoglobulins.  These were observed as 6-11nm sized numerous hyperreflective 
globules at the level of the corneal epithelium and anterior stroma and obscured normal 
architectural detail of the cornea in cases of multiple myeloma. The development of the 
crystals can precede systemic evidence of multiple myeloma by several years. (13) 
Anterior chamber: 
Anterior chamber leukemic cells and flare, pseudohypopyon and hyphema can 
occur in the anterior chamber. A shallow anterior chamber can be present due to iris 
swelling secondary to leukemic infiltrate.Anterior chamber infiltration–simulating 
hypopyon (pseudohypopyon) can occur in multiple myeloma. (16)A pseudohypopyon is 
characterized by its persistence and irregular contour, which suggest clumping of 
neoplastic cellular material rather than the layering of neutrophils, as in anterior uveitis. 
Bronstein reported plasma cells floating free in the anterior chamber and adhering to the 
posterior cornea .(11) 
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Uvea: 
Cysts of the ciliary body represent the most common ocular manifestations in 
myeloma patients. Infiltration of the iris has also been reported, simulating a non 
granulomatous uveitis. Metastatic carcinomas of the iris, which typically appear as solid, 
amelanotic masses, occasionally are shed cells that form a hypopyon in the anterior 
chamber(14). 
Infiltration of the anterior segment by leukemic cells occurs rarely in patients. It 
usually occurs in patients with acute leukemia but may also occur in patients with chronic 
leukemia. In some patients, usually children, a spontaneous hypopyon-hyphema is the 
first evidence of the disease, whereas in other patients with known leukemia, involvement 
of the iris and anterior segment is the first or only evidence of relapse of the disease. 
(12)The condition is characterized by conjunctival injection, symptoms of acute 
iridocyclitis, and a hypopyon that may be tinged with blood.  
There may be elevated intraocular pressure. Infiltration of the iris may be diffuse 
or nodular. Diffuse infiltration discolors the iris, which appears to be covered by a 
whitish-gray film, and it produces hyperchromia or hypochromia iridis when the process 
is unilateral. If there is nodular infiltration, the nodules are seen over the iris. The 
diagnosis of anterior segment involvement by leukemia can be confirmed by paracentesis 
with cytologic examination of the aqueous humor. The condition can be treated 
effectively with low-dose irradiation to the anterior portion of the globe.(17) 
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Neuro-ophthal manifestations: 
Third nerve palsy, lower motor neuron facial nerve palsy and 6th nerve palsy have 
been reported in association with leukemias.CLL can present with acute optic neuropathy 
associated with cerebrospinal fluid evidence of meningeal spread of malignant cells 
.Visual loss in myeloma is usually caused by compression or infiltration of the optic 
nerves by tumor.  The mechanism of optic neuropathy in this case is probably related to 
infiltration of the optic nerve meninges by malignant plasma cells and impaired vascular 
supply caused by aggregated intraluminal plasma cells and monoclonal 
hypergammaglobulinemia. (18) 
In one study, neuro-ophthalmic symptoms resulting in diplopia or visual 
disturbances were reported.  Neurological complications of leukemia are caused by a 
variety of different processes.(15) 
1. Neurologic injury may be caused by leukemic invasion of the leptomeninges, 
parenchyma, spinal cord, nerve roots, and peripheral nerves. 
 2. Leukemia may cause cerebrovascular disorders, both hemorrhagic and 
ischemic, by obstructing intracranial vessels.  
3.Neurologic sequelae may result from the various forms of treatment of the 
disease. 
4.Paraneoplastic.  
In most cases, however, leukemic involvement of the CNS occurs from 
hematogenous spread or by direct invasion from adjacent affected bone marrow.(19) 
36 
 
CNS leukemia is diagnosed by cerebrospinal fluid (CSF) analysis, requiring a minimum 
of five white blood cells per microliter and the presence of leukemic blast cells by 
cytospin technique. Since the advent of successful therapy of leukemia, the meninges 
have become the major site of leukemic relapse.  
With the advent of intrathecal chemotherapy and cranial irradiation as routine 
CNS prophylaxis, the incidence of meningeal leukemia has declined to approximately 
10%. For those who suffer meningeal involvement following radiation therapy, however, 
prognosis is poor. Meningeal involvement occurs more commonly in acute lymphoblastic 
leukemia than in acute myeloblastic leukemia and is rare in the chronic lymphocytic 
leukemias .(21) 
Meningeal leukemia may produce a variety of symptoms from single as well as 
multiple cranial neuropathies and may also cause increased ICP. Affected patients may 
thus develop headache, meningismus, nausea, vomiting, papilledema, increasing lethargy, 
and focal neurologic signs, including diplopia from ocular motor nerve paresis.  
In most cases, leptomeningeal and parenchymal infiltration occurs at a relatively 
late stage of the disease after the diagnosis is established, but this is not always the case. 
In a series of 30 children with neurological presentations of malignancy, one-third had 
acute leukemia. Papilledema and ocular motor neuropathies  may be presenting 
manifestations of acute lymphocytic leukemia. Leukemic involvement of the brain 
parenchyma is usually an extension of meningeal infiltration, but rare autopsy results 
document isolated leukemic parenchymal collections. These may be the result of a 
mechanism other than invasion from the meninges or from treatment that suppresses 
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meningeal leukemic cells but spares those deep within the parenchyma. Parenchymal 
involvement is usually perivascular.  
Chloromas are usually single, but they may be multiple. They may arise in various 
locations in the CNS parenchyma and dura. They are isointense to white matter on 
magnetic resonance (MR) T1- and T2-weighted images and are isointense to hypointense 
on computed tomographic (CT) imaging, enhancing with contrast. 
Leptomeningeal infiltration can lead to infiltration of the intracranial portions of 
the optic nerves and optic chiasm. In most patients, visual loss may be slow and 
progressive, responding to radiation therapy, or extremely rapid.  
Cerebrovascular disorders may produce neurological dysfunction in patients with 
leukemia. The majority is hemorrhagic, caused by invasion of blood vessel walls by 
leukemic cells, thrombocytopenia, sepsis, and disseminated coagulopathy. Blast crisis, 
extreme leukocytosis, and thrombocytopenia are predisposing factors. 
Intracranial hemorrhage contributes to mortality in 10 to 21% of leukemic 
patients. Cerebral ischemia is less common than hemorrhage and may result from arterial 
or venous obstruction. In leukemic patients, cerebral venous thrombosis is the most 
common form of infarction, resulting in focal neurologic deficits, increased ICP, and 
papilledema. Arterial infarction may involve large vessels, cause lacunar events, or result 
from septic emboli.(22) 
Neurological disturbances in patients with Hodgkin's disease may result from 
involvement of the intracranial portion of the CNS, the spinal cord, or the peripheral 
nervous system (PNS). According to some authors, involvement of the nervous system in 
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patients with Hodgkin's disease occurs in 13 to 15% of all cases , although a review of 
2,185 patients with Hodgkin's disease found only 12 (0.5%) who developed neurological 
symptoms, signs, or both .(23)This discrepancy may be related to increasingly early 
diagnosis and treatment of this condition. Most examples of neurological involvement are 
secondary, occurring from discrete or diffuse metastases via meningeal vessels or from 
direct tumor extension. 
Ocular abnormalities associated with Hodgkin's disease include uveitis and 
retinopathy, keratitis sicca with bilateral enlargement of the parotid glands, and 
keratitis with vascularisation.  
Because of its proximity to the base of the skull and its long extradural course, the 
Abducens nerve is the cranial nerve most commonly affected by multiple myeloma, and 
it is also commonly involved by plasmacytomas located at the base of the skull. The 
dysfunction may be unilateral or bilateral. It may be isolated, or it may occur in 
association with other cranial neuropathies, including optic neuropathy. Cranial nerves 
other than the abducens nerve, including the vestibulocochlear and trigeminal nerves and 
the other ocular motor nerves, can be damaged by multiple myeloma and plasmacytomas. 
As with Abducens nerve paresis, paresis of the oculomotor or trochlear nerves that occurs 
in these settings can be isolated or associated with other neurological abnormalities. The 
paresis may be the first sign of the disease, or it may occur late in the course of the 
disease. Rare cases of ocular motor nerve paresis are bilateral, thus mimicking an 
intrinsic brainstem process, but most are unilateral. 
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Orbit: 
Orbital infiltrations are reported in leukemia. Orbital plasmacytoma can be the 
first manifestation in certain cases of multiple myeloma . All types of leukemia may 
involve the orbit; however, such involvement occurs more frequently in acute leukemia 
than in chronic leukemia. Leukemia is therefore not an infrequent cause of proptosis in 
children. Various authors report that 2 to 11% of children with proptosis have some form 
of acute leukemia. The orbital involvement may be related to infiltration of soft tissue by 
leukemic cells, to hemorrhage, or to both. 
Orbital infiltration in leukemia causes proptosis, diplopia, edema of the eyelids, 
chemosis of the conjunctiva, and moderate to severe pain, thus mimicking an orbital 
cellulitis. It usually occurs in patients with previously diagnosed leukemia, but in some 
cases, it is the first evidence of the disease. 
Leukemic cells may infiltrate almost all of the structures in the orbit, including the 
extraocular muscles, fat, and lacrimal gland.Leukemic infiltration may even extend 
beyond the confines of the orbit into the paranasal sinuses. It is usually diffuse, but in 
some patients, the infiltration produces a relatively well-circumscribed mass of leukemic 
cells. Although such a mass can accompany any form of leukemia and can be observed in 
patients with chronic leukemia after long periods of remission, it occurs most often in 
patients with acute myelogenous leukemia. 
 In such patients, the mass may have a characteristic greenish appearance caused 
by the pigmented enzyme myeloperoxidase and is called, as noted above, a granulocytic 
sarcoma or chloroma. The cause of granulocytic sarcoma is unknown, but cellular 
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immune deficiency may play an important role. Granulocytic sarcomas may appear at 
any time during the course of the leukemia and, like diffuse infiltration, may even occur 
months or even years before there is any evidence of other systemic disease. In patients 
with leukemia, bilateral involvement of the orbits is not uncommon. It is usually a poor 
prognostic sign. 
Granulocytic sarcoma or chloroma is an unusual localized tumor composed of 
cells of myeloid origin. Involvement of the orbit and the ethmoid sinuses presenting as 
proptosis is rare (22). 
Orbital involvement is a rare complication of Hodgkin's disease. The majority of 
cases occurs in patients with known Hodgkin’s disease and consists of infiltration of the 
eyelids, subconjunctival space, conjunctiva, soft tissues of the orbit, and lacrimal gland. 
Some patients with multiple myeloma may develop signs of an orbital process as the 
result of their myeloma. Such patients may present with proptosis, diplopia, visual loss, 
or a combination of these manifestations. Eye, brow, or orbit pain may be a prominent 
complaint, although this is by no means always the case.  
Some of these patients have multiple myeloma at the time their orbital symptoms 
and signs develop, but in most, the orbital process is the first sign of the disorder. In these 
patients, myeloma cells usually infiltrate orbital soft tissue. The infiltration is often 
diffuse, affecting all of the tissues in the orbit, including fat, extraocular muscles, and 
lacrimal gland, but it also may be limited, presenting as focal enlargement of the lacrimal 
gland or as a well-defined mass. Orbital involvement is usually unilateral, but it may be 
bilateral.  
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POSTERIOR SEGMENT MANIFESTATIONS 
The posterior segment manifestations of haematological malignancies can be 
divided into: 
1)     Direct  manifestations (leukemic infiltrates), 
2)     Possible direct manifestations (such as white-centered retinal haemorrhages), 
3)    Manifestations of complications of malignancy 
 (chiefly anemia, thrombocytopenia, and hyper viscosity states) 
4)    Opportunistic infections. 
5)    Chance or unrelated findings. 
Leukemic retinopathy, the term most commonly used to denote the fundus 
manifestations of anemia, thrombocytopenia, and increased blood viscosity seen in 
patients with leukemia. In general, the term does not necessarily refer to frank leukemic 
proliferation. The changes of "leukemic retinopathy" may be more commonly seen with 
the acute leukemias but the frequency with which they occur has not been adequately 
studied to be certain. Although perivascular sheathing may be due to actual perivascular 
infiltrates, tortuous dilation of the retinal veins probably is not. The veins and arteries 
may assume a yellowish tinge both because of anemia and leukocytosis. Retinal 
hemorrhages may be seen, often at the posterior pole. The hemorrhages may be 
subretinal, deep retinal, superficial retinal, or preretinal, and there may be breakthrough 
bleeding into the vitreous cavity. They may have a blot or blotch shape, flame shape, or 
they may have white centers. 
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Cotton-wool spots may be the presenting abnormality that precipitates the 
systemic evaluation leading to the diagnosis of leukemia. The cotton-wool spots may be 
due to local factors, such as an abnormally large cell or cluster of cells occluding retinal 
arterioles, and may not be related to the overall peripheral blood composition. In general, 
hematologic parameters are not associated with the presence of cotton wool spots. 
Cotton-wool spots and hemorrhages can resolve in patients with chronic disease. 
Retinal hemorrhages and cotton-wool spots related to anemia or thrombocytopenia 
are common in patients with non-Hodgkin's lymphoma, but direct retinal involvement of 
the retina in patients with systemic lymphoma is extremely rare. Hodgkin’s disease can 
cause periphlebitis, focal chorioretinitis, vitritis, and optic disc edema. Patients with 
"numerous white deposits in the retinal periphery," chorioretinitis, Roth's spots, and 
perivascular retinitis have been reported.  
Rosenthal emphasized that optic nerve infiltration occurs predominantly in 
children with acute lymphocytic leukemia (ALL) and must be differentiated clinically 
from papilledema. Patients with leukemic infiltration of the prelaminar optic nerve 
typically have marked swelling of the optic disc with a fluffy superficial infiltrate and 
variable hemorrhage . The visual acuity may be minimally or severely affected. With 
retrolaminar optic nerve infiltration, moderate to marked disc elevation and edema with 
variable hemorrhage may be present and marked vision loss is generally observed.  
Optic nerve infiltration may occur despite prophylactic brain irradiation in 
leukemia because of the shields employed to protect the eyes. In general, optic nerve 
infiltration by leukemia responds well to radiotherapy (with or without intrathecal 
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chemotherapy). Brown and co-workers reported the case of a patient with acute 
promyelocytic leukemia and optic disc infiltration who showed complete resolution with 
oral all trans-retinoic acid alone. 
Retinal or preretinal infiltrates: 
Leukoembolization of the retina with resulting ischemia from infarction of the 
retinal capillary bed is seen in numerous conditions manifesting as Purtscher’s-like 
retinopathy . The mechanism of micro vascular occlusion in these diseases is generally 
believed to be leukocyte aggregation resulting from activation of complement factor C5a. 
 This aggregation hypothesis is supported by evidence of increased blood viscosity 
and leukostasis in the vasculature of brains of patients who have died from leukemia (7). 
The clinical presentation of severe peripheral retinal ischemia may be due to 
unrecognized leukoembolization of the retinal vasculature prior to the diagnosis of CML. 
The progressive retinal ischemia may exacerbate the secretion of angiogenic factors in 
the diseased retina and may lead to accelerated development of neovascular disease. 
Interestingly, recent studies have found that systemic blood plasma concentrations 
of angiogenic factors, including vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) are significantly increased in patients with CML, 
compared to healthy controls (8,9). Extravascular leakage of circulating VEGF and bFGF 
from incompetent vessels into the compromised retina may also act to increase the local 
tissue levels of these angiogenic factors and accelerate the clinical course of proliferative 
disease.  
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Leukemic infiltrates have been described by Kuwabara. A patient with chronic 
myelogenous leukemia with large gray-white nodules of varying sizes in the retina was 
reported. Gray-white streaks along vessels may be caused by perivascular leukemic 
infiltrates. Infiltrates are also observed in the retina in systemic lymphomas also. 
Choroidal infiltrates: 
Although the choroid is probably the most commonly affected part of the eye in 
leukemias, clinical signs of choroidal involvement are often subtle unless there is 
overlying retinal changes which bring them to attention. Serous retinal detachment 
overlying choroidal infiltrates or overlying frank choroidal masses are important clues. 
Serous retinal detachment overlying areas of choroidal infiltration have been reported in 
patients with CLL, ALL, CML and AML. 
 Serous retinal pigment epithelial (RPE) detachment has also been reported in a 
patient with acute lymphoblastic leukemia. The serous retinal and RPE detachments can 
be the presenting manifestation of the leukemia. Eventually, as the changes resolve, 
coarse clumping of the RPE is seen. Areas of RPE hyperplasia including heaped-up 
masses of pigment epithelium surrounding leukemic cells. The choroid is commonly 
infiltrated by leukemic cells during the course of both acute and chronic leukemia. In 
fact, Leonardy et al. found the choroid to be the most frequently involved site (31.1%) of 
ocular involvement in an autopsy series of leukemic patients. Abnormalities that are 
visible during ophthalmoscopy, however, are rare. Nevertheless, some patients develop 
generalized serous detachment of the retina, retinal pigment epithelium, or both, 
associated with diffuse infiltration of the choroid by leukemic cells. Others develop 
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localized choroidal masses with overlying retinal and RPE detachment, and rare patients 
develop pigmentary changes in the RPE from interference of the blood supply to the RPE 
by leukemic cells that infiltrate the choroid. 
Vitreous infiltrates: 
Vitreous opacities may be manifestations of an intraocular malignancy. Moribund 
patients may show massive collections of tumor cells in the vitreous, but most patients 
with intravitreal hemorrhage have neoplastic cells in the vitreous only because their 
peripheral blood contains tumor cells. The cells do not appear to be preferentially 
replicating in the vitreous cavity. Leukemic cells have been found in the vitreous of 
patients with neovascularization of the disc. Disc neovascularization has also been seen 
in a patient with erythroleukemia although that patient also had diabetes. Vitreous 
involvement has been seen at the time of autopsy in patients with reticulum cell sarcoma, 
Burkitt's lymphoma, multiple myeloma, and Hodgkin's disease In leukemia the internal 
limiting membrane usually acts as a barrier to infiltration of the vitreous by leukemic 
cells; however, such infiltration occasionally occurs. Terson syndrome occurs in rare 
cases. 
White-centered retinal hemorrhages (Roth spots): 
Most patients are asymptomatic or have visual loss related to the underlying 
disease process. White-centered retinal hemorrhages may be isolated or more numerous. 
Depending on the association, white-centered hemorrhages most likely result from 
localized capillary rupture from any anoxic insult or sudden elevation in venous pressure. 
The white center is a fibrin platelet aggregate that results during the physiologic healing 
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process. The collections of abnormal cells are white blood cells (in leukemia/lymphoma) 
or platelets (in multiple myeloma). The most common underlying factors are anemia and  
thrombocytopenia. 
Manifestations of hyper viscosity: 
Whole-blood hyper viscosity may lead to veno-occlusive disease, micro aneurysm 
formation, retinal hemorrhages, and retinal neovascularization. The most common 
manifestation is probably a mild or "hyperpermeable" central retinal vein occlusion. A 
systemic hyper viscosity state should be suspected in patients with bilateral changes. 
Peripheral retinal neovascularization has been reported in patients with CML in 
association with peripheral capillary nonperfusion. Most cases have associated extreme 
leukocytosis or thrombocytosis. Presumably, the hyperviscosity state leads to peripheral 
nonperfusion and subsequent development of retinal  neovascularization. In general, the 
blood viscosity begins to increase remarkably only with white blood cell counts of 
greater than 50,000. In multiple myeloma, increased viscosity results in reduced flow of 
blood through the eyes and produces the characteristic changes of dilatation of the retinal 
arteries and veins, hemorrhages, microaneurysms and areas of capillary closure. 
Micro aneurysm formation may be apparent, most frequently in the retinal 
periphery and mid periphery. If hyper viscosity is severe, retinal changes similar to those 
described in Waldenström's macroglobulinemia may be seen. Serous and exudative 
retinal detachments associated with multiple myeloma have also been reported. 
Reduction in the abnormalities producing hyper viscosities can reverse retinal changes. 
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Optic Neuropathy: 
In multiple myeloma, the initial clinical manifestation is usually bilateral optic 
disc swelling. The infiltration of optic nerve meninges by malignant plasma cells and 
impaired vascular supply by intraluminal plasma cells and monoclonal 
hypergammaglobulinemia is the mechanism behind optic neuropathy. The infiltration and 
compression of optic nerve causes visual loss in myeloma.  
In acute lymphoblastic leukemia also, optic nerve head infiltration is seen. 
Leukemic infiltration of orbital portion of optic nerve is usually a preterminal 
phenomenon in the past but now by the use of prophylactic CNS irradiation and 
chemotherapeutic agents , the long term survival has improved and the leukemic invasion 
of optic nerve has become uncommon and has become a treatable cause of vision loss.In 
acute leukemias especially , the lymphocytic type , clinical evidence of infiltration of 
orbital portion of the optic nerve is common. 
Histopathologically, the optic nerve infiltration is only marginally more common 
in acute than chronic leukemia. Mostly at the time of optic nerve head infiltration ,there is 
CNS involvement or active bone marrow disease but it may also be the first manifestation 
of relapse or recurrent leukemia. 
Two patterns of leukemic infiltration are: 
1. Retro laminar ( which is common) and 
2. Pre laminar . 
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In the pre laminar and laminar involvement, there is fluffy, whitish infiltrate in the 
substance of the disc, along with disc swelling and hemorrhage. If the infiltrate does not 
include the macula the central visual acuity is retained or minimally reduced. 
In the retro laminar involvement, fluffiness is almost absent in such cases, but an 
associated retinopathy that includes evidence of both arterial and venous occlusion may 
be present.  
Although leukemic infiltration of the retro laminar portion of the optic nerve may 
be compatible with normal visual function, there is usually moderate to severe loss of 
vision. Because both patterns of leukemic infiltration of the optic nerve are associated 
with some degree of optic disc swelling, they must be differentiated from papilledema. In 
many cases, this is extremely difficult, not only because in all three settings there is optic 
disc swelling associated with minimal if any visual loss, but also because it is not unusual 
for optic nerve infiltration to occur simultaneously with meningeal infiltration and 
increased ICP , particularly in the setting of treatment of acute promyelocytic leukemia 
with all-trans retinoic acid . 
For this reason, in all patients who present with optic disc swelling in the setting of 
leukemia, neuroimaging studies and a lumbar puncture must be performed. Both CT 
scanning and MR imaging typically show generalized enlargement of the affected optic 
nerve often associated with a cuff of enhancement surrounding the nerve that represents 
leukemic cells. Ocular echo graphy may also be helpful in this setting, showing that the 
nerve itself is enlarged. 
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TREATMENT OF OCULAR INVOLVEMENT IN MALIGNANT DISORDERS: 
The treatment of leukemia is discussed below; however, it is appropriate here to 
emphasize that the optimum treatment for infiltration of the optic nerve is prompt local 
irradiation. This is typically performed urgently and followed by intrathecal as well as 
systemic chemotherapy. 
Patients who receive about 2000 cGy to the posterior globe and orbit usually show 
a rapid resolution of their disc swelling and infiltration that may be accompanied by 
improvement in vision. 
In addition to infiltration, neovascularization of the optic disc occurs in patients 
with acute leukemia, particularly in the lymphocytic type.  
An optic chiasmal syndrome may be produced by a plasmacytoma that mimics a 
pituitary adenoma. Homonymous field defects in patients with multiple myeloma may 
result from compression or infiltration of the post chiasmal visual sensory pathways by 
myeloma cells, or from secondary effects of the disease (e.g., infarction of the occipital 
lobe), or from infectious complications of the disease, its therapy, or both (e.g., 
intracranial abscess formation). 
OPPORTUNISTIC INFECTIONS: 
Potentially life threatening infections unusually occur during periods of 
neutropenia in patients with leukaemia , which may be result of either chemotherapy of 
due to the underlying disease. A wide variety of infections by bacterial, viral, fungal and 
protozoal organisms are known to occur in these patients. 
50 
 
Cytomegalovirus(CMV) is one of the common viruses infecting immunocompromised 
host,  considerably involving the neuroectodermal tissue. CMV virus invades the retina 
causing retinal necrosis, haemorrhage, vascular sheathing and combined rhegmatogenous 
and exudative retinal detachment.  Other viruses causing necrotising retinitis in 
immunocompromised hosts are herpes simplex, varicella and mumps virus. 
Granulomatous uveitis has been reported to occur in mumps.  
Peripheral corneal ulcer, keratitis and scleritis are found to occur in herpes zoster. 
Fungal causes of ocular infection are common in leukaemias.  Uveitis and retinitis with 
characteristic cotton balls in vitreous occurs in candida infection. Aspergillus infection is 
also common in leukemic patients.  
Pseudomonas infection is common in immunocompromised leukaemic patients 
starting occasionally as blepharoconjunctivitis which spreads causing orbital cellulitis. 
Sweet’s syndrome is worth mentioning in this context which is characterised by sudden 
fever, neutrophilic leucocytosis , erythematous and tender pseudo vesiculated plaques or 
nodules that readily respond to corticosteroid therapy Endophthalmitis with potentially 
lethal effects upon visual potential is also recognised to occur in acute leukaemia. 
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TOXICITY TO ANTILEUKAEMIC DRUGS 
Many novel anticancer drugs have been introduced in the past few years , both in 
research protocols and in routine clinical practice. Full range of side effects is not known 
still for many of these. A few important drugs causing ocular side effects will be 
mentioned here. Posterior sub capsular cataract has been reported to occur with 
busulphan.  
Vincristine and vinblastine clinically affects the motor nerves of the eye (CN III, 
IV,VI & VII), are toxic to CNS and causes corneal hypoaesthesia. Vincristine causes 
optic atrophy. Cystosine-Arabinoside topically or systemically has been shown to be 
toxic to the corneal epithelium.   
 Patients on cyclosporine often receive other drugs causing dystonic eye 
movements which can delay the diagnosis and treatment resulting in irreversible 
neurological defect and hence recognition of this association is very important. 
Patients with leukemia may develop neurological dysfunction from the toxic 
effects of drugs used to treat the leukemia and from infections that occur in the CNS of 
patients who are debilitated or immune suppressed. With conventional cranial 
radiotherapy, neurotoxicity is more often sub acute and delayed, rather than acute. 
Intrathecal  methotrexate  may cause chemical meningitis. A sub acute 
leukoencephalopathy occurs in patients treated with methotrexate and is thought to be 
caused by direct toxicity of the drug. It is more commonly encountered when 
methotrexate is given in high doses intravenously and intrathecally and/or combined with 
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cranial irradiation, and it occurs in up to 50% of children undergoing such therapy. Other 
drugs may produce a similar encephalopathy, a peripheral neuropathy, or both 
BONE MARROW TRANSPLANT (BMT)/ GVHD 
Bone marrow transplantation may follow development of ocular symptoms and 
signs , either due to radiation treatment or GVHD occurring along with it. Ocular 
problems are more frequently recognised due to the recent improvements in systemic 
management of these patients. GVHD leads to ocular manifestations like cicatricial 
lagophthalmos, ectropion of lid, keratoconjunctivitis sicca , sterile and pseudo 
membranous conjunctivitis, corneal epithelial defects, corneal ulceration and melting and 
uveitis. Corneal keratinisation may occur in severe cases. Cataracts commonly occur after 
autologous bone marrow transplantation. 
Patients with chronic GVHD manifest frequently than  patients with acute GVHD. 
Severe chronic GVHD is associated with severe ocular complications leading to poorer 
survival. Sjogren syndrome or scleroderma like crisis are often the presenting features of 
chronic GVHD. The picture of acute and/or chronic transplant reaction of the host cells 
against grafted bone marrow has become more frequent since the era of BMT. 
 Acute GVHD of conjunctiva occurs in four stages namely injection/ exudation 
and chemosis / formation of pseudomembranes / defects of  the corneal epithelium. 
Fibrotic Arlt lines of  the tarsal conjunctiva is a pathognomonic sign for chronic GVHD. 
Thus screening for ocular sicca should be done in asymptomatic patients and artificial 
tear replacement must be initiated. 
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Impairment of visual acuity following BMT commonly occurs due to cataract 
formation, probably related to steroid intake and total body irradiation for pre-transplant 
conditioning. Ocular manifestations of BMT are not uncommon in children, most 
common anterior segment problem being the rear film dysfunction.  
Posterior segment involvement is less common to occur; unilateral epiretinal 
membrane and or bilateral discrete multiple chorioretinal hypo pigmented lesions in the 
middle to peripheral part of retina are found to occur. The most important complication 
anticipated is amblyopia in immature eyes is probably due to the high incidence of 
cataract. 
Ischaemic retinopathy is also found to occur following BMT. The aetiology is 
unclear, probably multifactorial, related to treatments like cyclosporine or radiation.  
 
  
 
 
PART - II 
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AIMS AND OBJECTIVES: 
1. To observe the incidence and types of retinopathy in various disorders of blood. 
2. To determine the diagnostic and/or prognostic importance of lesions seen 
3. To study the progression / resolution of lesions with treatment of blood dyscrasias 
STUDY DESIGN: 
200 eyes of 100 patients were examined in this prospective, comparative, 
Hospital- based study. 
MATERIALS & METHODS: 
100 patients diagnosed with blood dyscrasias presenting at Stanley Medical 
College Department of ophthalmology, and other patients referred from allied 
departments were enrolled in the study 
This study was done in accordance with the rules of the ethical committee. 
All patients were informed about the purpose of the study and written and informed 
consent was obtained. 
Patients falling within the inclusion criteria were included in the study. A detailed 
history taking and detailed physical evaluation. The evaluation was done after obtaining 
informed written consent  in the patients’ own language. 
Ocular evaluation included: 
• Recording best corrected visual acuity 
• Anterior segment examination using Slit lamp 
• Intraocular pressure measurement by Goldman Applanation Tonometry 
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• Field charting with Octopus analyser 
• Dilated fundus examination by means of direct and indirect ophthalmoscope 
• Fundus photography. 
• Fundus Fluorescein angiogram , performed when indicated. 
The patients also underwent relevant haematological investigations to find out the 
type of haematological disorders and its correlation with the clinical picture. 
These patients were followed every two months with detailed ocular examination for 
the evolution of lesions, till resolution. 
INCLUSION CRITERIA: 
• All cases of newly diagnosed Blood dyscrasias. 
• All age groups 
EXCLUSION CRITERIA: 
• Patients with associated systemic diseases such as diabetes, hypertension. 
• Patients with ocular trauma. 
• Patients with other ocular diseases(Eg, CRVO ,Eale’s disease) 
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OBSERVATION: 
 
100 patients were included in our study. 
Out of which, 37 were non- malignant and 63 malignant disorders of the blood. 
 
TOTAL NON MALIGNANT 
DISORDERS 
MALIGNANT 
DISORDERS 
100 37 63 
 
 
 
 
 
37 
63 
INCIDENCE OF BLOOD DYSCRASIAS 
NON MALIGNANT 
DISORDERS 
MALIGNANT DISORDERS 
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NON- MALIGNANT DISEASES: 
The following were the non - malignant diseases observed. Commonest disorders 
of non- malignant etiology were anemias of which Iron-deficiency was the most common 
followed by Aplastic Anemias. 
DISEASES NUMBER OF PATIENTS 
IRON DEFICIENCY ANEMIA 14 
APLASTIC ANEMIA 8 
MEGALOBLASTIC ANEMIA 5 
HEMOLYTIC ANEMIA 4 
ANEMIA OF CHRONIC DISEASE 2 
THALASSEMIA 1 
IDIOPATHIC THROMBOCYTOPENIA 3 
 
 
 
IRON DEFICIENCY ANEMIA APLASTIC ANEMIA 
MEGALOBLASTIC ANEMIA HEMOLYTIC ANEMIA 
ANEMIA OF CHRONIC DISEASE THALASSEMIA 
IDIOPATHIC THROMBOCYTOPENIA 
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1.SEX DISTRIBUTION: 
Among the 100 patients, with non malignant disorders, 24 were male and 13 
female, while among malignant disorders 40 were male and 20 female. 
 
NON MALIGNANT DISORDERS 
Male Female 
24 13 
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2.AGE INCIDENCE: 
AGE 
GROUP 
NO OF 
PATIENTS 
OCULAR 
FEATURES 
PERCENTAGE 
<20 8 5 63% 
20-40 11 11 100% 
40-60 10 7 70% 
>60 6 2 33% 
 
 
Non malignant disorders of the blood were most common in the age group of 20- 40 
yrs (32%) with all 11 patients in the age group demonstrating ocular lesions. 
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3. INCIDENCE OF OCULAR FEATURES IN NON MALIGNANT DISORDERS 
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IRON DEFICIENCY ANEMIA 
(IDA) 14 12 86% 
APLASTIC ANEMIA (AA) 8 8 100% 
MEGALOBLASTIC ANEMIA 
(MA) 5 3 60% 
HEMOLYTIC ANEMIA (HA) 4 1 25% 
ANEMIA OF CHRONIC 
DISEASE (ACD) 2 1 50% 
THALASSEMIA (THAL) 1 1 100% 
IDIOPATHIC 
THROMBOCYTOPENIA (ITP) 3 2 67% 
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3. SYMPTOMS AT PRESENTATION: 
 
SYMPTOMS AT 
PRESENTATION 
NO OF PATIENT PERCENTAGE 
ASYMPTOMATIC 19 56% 
DEFECTIVE VISION 8 24% 
RED EYE 7 20% 
 
 
 
 
Most patients who presented with anemia were asymptomatic 19 (56%) , while 
11patients (29%) had some complaints of defective vision while 7 patients (15%) had 
complaints of red eye due to sub-conjunctival haemorrhages. 
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4. VISUAL ACUITY AT PRESENTATION: 
Vision 
 
Better eye Worse eye 
6/6- 6/9 33(61%) 20(37%) 
6/12- 6/18 11(20%)  10(18%) 
6/24 – cf 3m 9(16%) 7(13%) 
Cf 3m – PL 3(5%) 1(2%) 
  
 
 
 
 
 
27 patients (73%) of non malignant diseases of the eye had good visual acuity (6/6 – 
6/18)  at presentation , while  10 (27%) eyes showed poor visual acuity , due to preretinal 
hemorrhage,involving the macula and disc edema in one case. 
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5. INCIDENCE OF OCULAR MANIFESTATIONS: 
Ocular manifestation No. of cases Percentage 
Conjunctival Pallor 34 92% 
Retinal Hemorrhage 23 62% 
Cotton wool spots 21 57% 
Pre-retinal hemorrhage 16 43% 
Roth spots 5 14% 
SCH 7 19% 
Disc Edema 1 0.3% 
 
 
Non malignant diseases had conjunctival pallor (92%) as the most common 
manifestations followed by retinal hemorrhage (67%) and cotton wool spots (52%) . One 
case of unilateral disc edema was noted(0.3%). 
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RETINAL HEMORRHAGES 
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COTTON WOOL SPOTS 
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ROTH SPOTS 
 
 
 
 
 
  
67 
 
PRE – RETINAL HEMORRHAGES  
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DISC OEDEMA 
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7.RESOLUTION OF LESIONS AND FOLLOW UP: 
 
   RESOLUTION AND FOLLOW UP  
Total    AA ACD HA IDA MA THAL ITP 
 Complete 
Resolution 
Lesion 
Persisted 
 
No follow 
Up 
 6  1 10 3 1 1 22 
  0 1  1   0 2 
 
  
2 
 
 
  
1 
   
1 
 
4 
 Total 8 1 1 12 3 1 2 28 
 
 
Most non malignant disorders showed resolution except two, one a case of severe iron 
deficiency with poor adherence to treatment and other with aplastic anemia due to 
underlying disease. 
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MALIGNANT DISEASES: 
The malignant diseases enrolled in the study are : 
DISEASES NUMBER OF PATIENTS PERCENTAGE 
NON- HOGKIN 
LYMPHOMA 
29 46% 
CLL 7 11% 
AML 6 9.5% 
PARAPROTEINEMIAS 6 9.5% 
HODGKINS LYMPHOMA 5 8% 
CML 5 8% 
ALL 5 8% 
 
 
 
Non- Hodgkin’s lymphoma was the most common malignant disorder in our study. 
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1. AGE INCIDENCE: 
        AGE GROUP NO. OF PATIENTS PERCENTAGE 
<20 YRS 16 25% 
20- 40 20 32% 
40- 60 17 27% 
>60 10 16% 
 
 
 
  
 
 
 
Malignant haematological disorders were most commonly seen in the age group of 
20 – 40 years (32% ). 
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2.SEX DISTRIBUTION: 
 
MALIGNANT DISORDERS 
Male Female 
43 20 
 
 
SEX DISTRIBUTION AMONG MALIGNANT DISORDERS: 
 
 
 Malignant Disorders of the blood are more common in males (68%) 
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3.INCIDENCE OF OCULAR FEATURES IN EACH MALIGNANCY 
DISEASES 
NO. OF 
PATIENTS 
(63) 
LESIONS 
PRESENT 
(23) 
PERCENTAGE 
NON- HOGKIN 
LYMPHOMA 
29 8 27% 
CLL 7 3 43% 
AML 6 4 66% 
PARAPROTEINEMIAS 6 3 50% 
HODGKINS 
LYMPHOMA 
5 2 40% 
CML 5 1 20% 
ALL 5 2 40% 
 
Ocular findings were most commonly observed in cases of acute leukemias, AML and 
ALL followed by paraproteinemias. 
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RETINAL HEMORRHAGES 
 
 
  
75 
 
PRE – RETINAL HEMORRHAGE 
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ROTH SPOTS  
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(RE) SUPERO TEMPORAL BRANCH RETINAL VEIN OCCLUSION 
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PROPTOSIS  
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VITREOUS HEMORRHAGE 
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4. SYMPTOMS AT PRESENTATION: 
SYMPTOMS NO.OF PATIENTS PERCENTAGE 
Asymptomatic 42 66% 
Defective Vision 17 27% 
Proptosis 2 3% 
Field defects 1 2% 
Diplopia 1 2% 
 
 
 
 
Most patients had no ocular symptoms at presentation and 21 were symptomatic. 
17 patients (27%) presented with defective vision. Two patients presented as proptosis 
and later were diagnosed as haematological malignancy. 
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5.OCULAR MANIFESTATIONS IN MALIGANT DISORDERS: 
 
 
 
 
 
 
 
 
 
 
 
Retinal hemorrhages in the form of superficial hemorrhages were the most 
common finding followed by cotton wool spots and pre- retinal hemorrhages. 
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LESIONS INCIDENCE PERCENTAGE 
Retinal hemorrhage 18 28% 
Cotton wool spot 16 25% 
Pre retinal hemorrhage 13 20% 
Hage with white centre 11 17% 
Vitreous hemorrhage 2 3% 
Proptosis 2 3% 
Papilledema 1 1.5% 
Cranial nerve palsy 1 1.5% 
Vascular occlusion 1 1.5% 
Vascular tortuosity 1 1.5% 
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6.VISUAL ACUITY AT PRESENTATION 
Vision 
 
Better eye Worse eye 
6/6- 6/9 40 (63%) 27 (43%) 
6/12- 6/18 24(3%) 11 (7%) 
6/24 – cf 3m 8(16%) 6(11%) 
Cf 3m – PL 4(14%) 3(6%) 
 
 
 
 
Most patients presented with good vision at presentation, while 33 %  had poor 
vision, commonly due to fundus changes including pre-retinal hemorrhages over the 
macula followed by vitreal haemorrhages. 
0 
5 
10 
15 
20 
25 
30 
35 
40 
6/6- 6/9 6/12- 6/18 6/24 – cf 3m Cf 3m - PL 
Better eye  
Worse eye 
84 
 
7.RESOLUTION AND FOLLOW UP 
  RESOLUTION AND FOLLOW UP  
Total   NHL HL AML ALL CML CLL MM 
Complete 
Resolution 
Lesion 
Persisted 
 
No follow 
Up 
CR 8 2 3 1 1 1 1 17 
LP 0 0 0 1 0 2 2 5 
NF 0 0 1 0 0 0 0 1 
Total 8 2 4 2 1 3 3 23 
 
 
 
Resolution of lesions was noted in most patients (74%), while persistence of 
lesions was seen in 22 % of the cases. 
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RESULTS 
NON MALIGNANT HEMATOLOGICAL DISORDERS: 
Among 100 patients, 37 were observed to have non – malignant disease of the 
blood, most common of them was Iron deficiency anemia (38%) , concurrent with studies 
done by Quadri et al (34 %). 
STUDY COMMON 
INCIDENCE 
AGE 
GROUP 
OCULAR FEATURES 
Lange et al Anemia(37%) 25- 60 Pallor > Retinal hemorrhages 
(70%) 
Holt J.M & 
Gordensmith 
Anemia(49%) 40-60 Retinal hemorrhages(67%) 
Rubenstein and 
Yanoff 
Anemia(22%) 20- 50 Retinal hemorrhages(41%) 
Merin S.& 
Freund 
Anemia (30%) 
(Nutritional) 
20 -40 Retinal hemorrhages(55%) 
Our study Anemia (38%) (Iron 
deficiency) 
20 -40 
(32%) 
Pallor > Retinal 
hemorrhages(62%) 
 
Our study showed comparable results with most other studies with non – 
malignant disorders of the blood most commonly were seen in the age group of 20 – 40 ( 
32%) with male preponderance (65%). Iron deficiency anemia was most commonly seen 
among female while aplastic anemia were most common in men. 
Visual acuity at presentation was good(6/6 to 6/18 ) in almost 70 % of the patients. 
10 patients presented with defective vision, of whom 9 were attributed to pre- retinal 
haemorrhages over the macula and one to unilateral disc edema (0.3%)  in one case of 
megaloblastic anemia.  
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          These ten cases were diagnosed by the ophthalmologist as cases of haematological 
disorders and further evaluated and treated. 
            Conjunctival pallor (92%)was most common ocular manifestation followed by 
retinal haemorrhages (62%) . Similar findings were noted by Lange et al who reported 
71% and Merin Freund  et al (63% ) retinal lesions. 
Aplastic anemias demonstrated the maximum association with ocular findings (100%). 
Of the 14 patients of Iron deficiency anemia, only one patient showed persistence 
of lesions. This was due to poor adherence to systemic treatment. The lesions in aplastic 
anemia, megaloblastic , haemolytic anemia and thalassemias showed resolution. One case 
of Anemia of chronic disease with underlying chronic renal failure showed persistence of 
lesions due to progression of the systemic disease. 
Among thrombocytopenia, resolution was noted in one patient while the other 
patient with lesions died during the period of follow up due to systemic complications. 
Retinal lesions persisted in one patient who was under treatment but this was not 
statistically significant due to small sample size. 
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MALIGNANT HEMATOLOGICAL DISORDERS: 
Among 100 patients enrolled in our study, 63 patients had malignant disorders of 
the blood , including Non –Hodgkin Lymphoma (46%), being the most common , 
followed by Chronic leukemias , acute leukemias and paraproteinemias. 
Comparison of incidence of ocular involvement (mostly metastasis and infiltrations) in 
patients with hematological malignancies in different studies : 
INVESTIGATOR INCIDENCE 
Allen and Straatsma(1961) 38 of 76(50%) 
Robb,Ervin et al(1979) 30-44 of 60(50-73%) 
Kincaid and Green(1983) 284 of 357(50%) 
Nelson et al(1983) 33 of 117(28%) 
Schachat et al (1989) 51 of 120(42%) 
Leonardy et al (1990) 42 of 135(31%) 
Our study 23 of  63(37%) 
 
The malignancies of blood were more prevalent in the age group of  20- 40 years 
(32%) as in studies done by Nelson et al and Leonardy et al. 
Majority of the patients were male 38 (60%) as compared to 25 females, possibly 
due to the increased incidence of haematological malignancies in males. 
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 Among 63 patients,  21 patients (33%) presented first to the Department of 
Ophthalmology with complaints of Defective vision in 17 patients (33%), Proptosis in 
two cases(3%) one in a case of AML and the other in a case of Multiple myeloma. 
Proptosis was found to be caused by tumour infiltration into the orbit on imaging.  
One case of multiple myeloma presented with defective vision and further was due 
to Branch Retinal Vein Occlusion, most likely secondary to hyperviscosity. Defective 
vision was noted due to pre-retinal haemorrhages, retinal and vitreous hemorrhage ,and  
in few cases due orbital infiltration. Shirley Fung et al reported in a study that among 8 
patients with multiple myeloma, 1 had retinopathy due to hyperviscosity while 3 others 
had orbital involvement. 
Among the 63 cases, 23(35%) had ocular manifestations of which 4 were in the 
anterior segment and 20 in the posterior segment. Retinal haemorrhages were the most 
manifestations (28%) followed by soft exudates (25%) as also reported in study by Holt 
JM& Gordensmith et al. 
One case of multiple myeloma presented with 6th nerve palsy and papilledema, 
due to CNS infiltration. A similar case was reported in a study by Osama Baddeb et al 
showing cranial nerve palsy secondary to CNS involvement. While one case of NHL 
presented with acute painless vision loss, due to vitreous hemorrhage. 
13 of the 23 showed lesions at presentation showed complete resolution after 
initiation of chemotherapy and consequent improvement in the blood picture. The rate of 
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improvement was inversely associated to the severity of the disease at the time of 
presentation. 
 Retinal lesions resolved over about 2 to 6 months. Cotton wool spots were earliest 
to resolve followed by superficial hemorrhages. Intraretinal and vitreous hemorrhages 
took the longest time for resolution. 6 of the 21 patients were lost to follow up. 
29 cases of Non – Hodgkin's lymphoma were included in the study which over 6 
months showed resolution in all of the 8 patients who demonstrated lesions at 
presentation and had statistical significance (p value <0.0001). 
In acute leukemias, of the total 11 cases, 6 showed lesions at presentation. In cases 
of AML, 4 of the six patients on treatment, 3 showed complete resolution. In 2 cases of 
ALL, lesions persisted in one patient due to incomplete treatment. 
Chronic leukemias showed lesions only in 4 patients. 2 of 3 cases of CLL showed 
resolution with one patient lost to follow-up due to death. (p value 0.0143) 
6 cases of Multiple myeloma were recruited in the study, three showed lesions of 
who only one had complete resolution. Lesions persisted in 2 patients due to incomplete 
treatment and relapse in the other. 
 
 
 
 
 
 
90 
 
CONCLUSION: 
• In this study, malignant disorders were more than non- malignant diseases. 
• Both disorders showed male preponderance with most diseases, while iron-
deficiency anemia was more common in females. 
• Most common age group was 20-40 years. 
• Iron- deficiency anemia was the most common non-malignant disorder and Non 
Hodgkins Lymphoma was the most common malignant condition in our study. 
• Aplastic anemia showed strong association with ocular lesions with almost all 
patients showing retinopathy. 
• 31 patients presented primarily to the ophthalmologist with defective vision as the 
most common symptom and following evaluation were diagnosed to have blood 
dyscrasias, thus emphasizing the need for thorough ocular screening. 
• Pallor was the most common sign in the anemia. Most common ocular 
manifestations among haematological disorders was retinal haemorrhages, 
followed by cotton-wool spots indicating retinal ischemia. 
• Ocular lesions showed rapid resolution with treatment except in cases of 
incomplete treatment in non- malignant disorders. Ocular manifestations persisted 
in malignant diseases due to relapse of the underlying disease. 
• Ocular manifestations are a frequent occurrence in blood dyscrasias and should be 
evaluated with a high index of suspicion when found. 
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PROFOMA 
 
Serial no: 
Name :  
Age: 
Sex: 
Occupation: 
Address : 
Ocular complaints: 
Associated  Systemic illness : 
Family history : 
OCULAR  EXAMINATION                                                                                                     
                                                                   RE                                    LE 
Vision 
Eyelids and lashes 
Extra ocular movements 
Slit lamp examination 
Conjunctiva 
Cornea 
Anterior chamber 
Iris  
Pupil 
Lens 
 IOP 
Colour vision:  
Fields : 
Amsler Grid: 
Fundus :  
 
 
90 D slit lamp: 
 
IDO: 
 
 
Fluorescein Angiography: 
Date:      Reactions( if any): 
Dye used: 
 
 
DIAGNOSIS: 
PATHOLOGICAL DIAGNOSIS: 
LABORATORY DIAGNOSIS: 
                
IMPRESSION: 
 
ADVICE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 KEY TO MASTER CHART  
ADNEXAL PROPTOSIS 
 
A 
 
LID SWELLING 
 
B 
ANTERIOR TORTUOUS CONJ VESSELS C 
 
SCH 
 
D 
 
HEMORRHAGES 
  POSTERIOR 
 
PRE RETINAL E1 
  
RETINAL E2 
  
VITREOUS 
HAGE E3 
  
WITH WHITE 
CENTRE E4 
 
CWS 
 
F 
 
HARD 
EXUDATE 
 
G 
 
VASCULAR 
TORT 
 
H 
 
VASC 
OCCLUSION 
 
I 
 
VITRITIS 
 
J 
 
VIT HAGE 
 
K 
 
PAPILLEDEMA 
 
L 
 
CRANIAL NERVE PALSY M 
 
DISC EDEMA 
 
N 
 
COMPLETE RESOLUTION 
LP PERSISTANCE OF LESIONS 
NF NO FOLLOW UP 
 
   CT COMPLETE TREATMENT 
UT UNDER TREATMENT 
 REL RELAPSE 
 R REMISSION 
 NF NO FOLLOW UP 
 IT INCOMPLETE TREATMENT 
   
 
 
 
 
  
M MALE 
F FEMALE 
6/6 – 6/9 1 
 6/12- 6/18 2 
 6/24 – 3M CF 3 
 3M CF – NIL 
PL 4 
 
   IDA IRON DEFICIENCY ANEMIA 
AA APLASTIC ANEMIA 
HA HEMOLYTIC ANEMIA 
MAMEGALOBLASTIC ANEMIA 
ACD ANEMIA OF CHRONIC DISEASE 
THAL THALASEMIA 
TP THROMBOCYTOPENIA 
HL HODGKIN LYMPHOMA 
NHL NON HODGKIN LYMPHOMA  
AML ACUTE MYELOID LEUKEMIA 
ALL ACUTE LYMPHOCYTIC LEUKEMIA 
CML CHRONIC MYELOID LEUKEMIA 
CLL CHRONIC LYMPHOCYTIC LEUKEMIA 
MM MULTIPLE MYELOMA 
 
 
 
 
Name age Sex Diagnosis RE vn LE vn RE LE COURSE 
FOLLOW 
UP 
Rajeshwari 18 F IDA 3 2 E2,F E2D CT CR 
Latha 32 F IDA 1 2 E2,D E1,E2,F CT CR 
Parvathi 37 F IDA 1 1 E2 E4,D CT CR 
Shiva kumar 71 M IDA 1 1 
  
CT   
Jemmy 26 F IDA 1 3 E4,D E2,F CT CR 
Santhy 17 F IDA 1 1 E2 E2 NF NF 
Marriyappan 65 M IDA 1 1 E2,F E2,F CT CR 
Ambiga 22 F IDA 1 3 
 
E1,F CT CR 
Aruna 29 F IDA 3 1 E2 E4 CT CR 
Radha 37 F IDA 1 3 E4,F E1 CT CR 
Maheshwari 26 F IDA 2 1 E2,F E2 CT LP 
Sujatha 43 F IDA 1 2 
 
E4 CT CR 
Sudhakar 79 M IDA 2 1 
  
CT 
 Viji 57 F IDA 1 1 
 
E1 CT CR 
Kamalhasan 19 M AA 3 3 E2,F E1,F UT CR 
Kalaiarasan 48 M AA 1 2 D E2,D UT CR 
Arumugam 28 M AA 1 3 E2,F E4,F UT CR 
Srinath 33 M AA 1 2 
 
E1,D UT CR 
Selvakumar 49 M AA 2 1 E2,F E1,F NF NF 
Eshwaran 12 M AA 2 1 E1 E1,D UT CR 
Tamilvannan 52 M AA 1 1 E2 E2,F NF NF 
Saravanan 51 M AA 2 1 
 
E2 UT CR 
Chinamalai 46 M MA 1 1 
  
CT 
 Palanisamy 27 M MA 2 1 E2,F E4,F CT 
 Shanharalingam 31 M MA 1 2 E1 E2,F CT CR 
Vadivelu 39 M MA 1 1 
  
CT 
 Nagarajan 14 M MA 2 1 
  
CT 
 Kmamakannan 54 M HA 1 1 
  
CT 
 Mohamed 22 M HA 2 1 E1,F E1,E2,F CT CR 
Anandan 57 M HA 1 2 
  
UT 
 Ashwin 19 M HA 1 3 
  
UT 
 Abdulla 72 M ACD 1 2 
  
UT 
 Arokiyam 64 F ACD 3 1 E2 D REL LP 
Raja 12 M THAL 1 1 
 
E2 UT CR 
Asha 26 F TP 1 1 
  
R 
 Raman 43 M TP 1 1 E1,F E2,F R CR 
Kandan 68 M TP 1 1 E3,F E2,F UT LP 
Kanagavalli 50 F AML 2 1 E4 E2,F R CR 
Kalavathi 15 F AML hm cf cf 
 
E2, L 
,M  NF NF 
Raman 19 M AML 1 1 E1,F E2,F R CR 
Deepan 22 M AML 1 1 
  
R 
 
Devakar 48 M AML 2 1 E2,F E4 R CR 
Bharathi 11 M AML 3 1 
  
R 
 Biravi 7 F ALL 1 1 
  
R 
 Jayalakshmi 13 F ALL 1 2 E4 E2,E4 IT LP 
Sathish 31 M ALL 1 3 E2,F E4 IT CR 
Sevaraj 28 M ALL 2 3 
  
R 
 Prasanna 19 M ALL 1 1 
  
R 
 Bhagya 73 F CLL 2 1 
  
R 
 Muthkumar 53 M CLL 1 1 
  
R 
 Murali 10 M CLL 3 1 E2,F E4,F R CR 
Murugan 21 M CLL 1 2 
 
E4,F R CR 
Malarvizhi 64 F CLL 1 1 
  
R 
 Ramesh 43 M CLL 1 3 
  
R 
 Balasubran 19 M CLL 1 2 E4,F E2,E4 NF NF 
Ahmed 45 M CML 2 2 
  
R 
 Varalakshmi 53 F CML 1 1 
  
R 
 Amalraj 31 M CML 2 3 
  
R 
 Radha 62 M CML 1 3 E2,F E2,E4,F R CR 
Divya 39 F CML 1 1 
  
R 
 Shivakumar 67 M MM 1 1 
  
R 
 Arumugam 52 M MM 1 1 
 
A R CR 
Ramayee 85 F MM 1 3 
 
I,H,F REL LP 
Ganapathy 71 M MM 3 1 
  
R 
 kannagi 61 M MM 1 1 E2 E4,F R LP 
Venila 58 F MM 1 1 
  
R 
 Murugan 32 M HL 1 1 E2,F E4,F NF NF 
Mohini 41 F HL 3 1 
  
R 
 Rajesh 38 M HL 1 1 
  
R 
 Sampath 32 M HL 1 3 
  
R 
 Vel  44 M HL 1 1 E3,F E2,F NF NF 
Rajan 58 M NHL 1 1 
  
R 
 Subramaniyam 23 M NHL 1 1 
  
R 
 Suresh 28 M NHL 1 3 E1,F E2,F NF NF 
Kokila 55 F NHL 1 1 
  
R 
 Bharath 57 M NHL 1 1 
  
R 
 Prashanth 16 M NHL 3 1 
  
R 
 Aradhana 7 F NHL 1 1 E4,F E2 R CR 
Gautham 14 M NHL 1 1 
  
R 
 Priya 21 F NHL 1 1 
  
R 
 Raju 76 M NHL 1 1 
  
R 
 Kumar 69 M NHL 1 1 
  
R 
 Selvam 33 M NHL 3 1 
  
R 
 Prabhakar 44 M NHL 1 1 E2,F E2,F NF NF 
Shanthi 50 F NHL 1 1 
  
R 
 Selvi 37 F NHL 4PL 1 K 
 
R 
 Priyanka 19 F NHL 1 1 
  
R 
 Sathish 10 M NHL 1 1 
 
A R CR 
Nagarajan 34 M NHL 1 1 
  
R 
 Pooja 17 F NHL 1 1 
  
R 
 Anandan 9 M NHL 1 3 
  
R 
 Ravichandran 12 M NHL 1 1 E1 E2 REL CR 
Kalaiselvi 39 F NHL 1 1 
  
R 
 Sakthivel 32 M NHL 1 1 
  
R 
 Sundaram 37 M NHL 1 1 
  
R 
 Kuppammal 80 F NHL 1 1 
  
R 
 Eshwaran 46 M NHL 1 1 E2 B R CR 
Mohan 51 M NHL 3 1 
  
R 
 Meiyappan 22 M NHL 1 1 E4,F E2,E3,F R CR 
Manoharan 14 M NHL 1 1 
  
R 
  
 
